|
February 9, 2012
|
| 16:27 EDT |  | VRTX |
| theflyonthewall.com: | Leerink's biotech and pharmaceuticals analysts hold a conference call | | Biotech Analysts Schimmer and Liang, along with Pharmaceuticals Analyst Fernandez, review the reimbursement process for drugs in France on an Analyst/Industry conference call. Relevant covered companies ACOR, AMGN, AMLN, AUXL, BIIB, BMY, GILD, HGSI, ITMN, JNJ, NVS, PFE and VRTX may be included on the Analyst/Industry conference call to be held on February 10 at 11 am. :theflyonthewall.com |
|
|
February 3, 2012
|
| 10:31 EDT |  | VRTX |
| theflyonthewall.com: | On The Fly: Analyst Downgrade Summary | | Today's noteworthy downgrades include: Research in Motion (RIMM) downgraded to Underperform from Hold at Jefferies...Cablevision (CVC) downgraded to Underweight from Neutral at JP Morgan...Edwards Lifesciences (EW) downgraded to Market Perform from Outperform at Wells Fargo...Rofin-Sinar (RSTI) downgraded to Neutral from Overweight at Piper Jaffray...Kforce (KFRC) downgraded to Hold from Buy at Deutsche Bank...Airgas (ARG) downgraded to Neutral from Buy at Goldman...Vertex Pharmaceuticals (VRTX) downgraded to Neutral from Buy at Goldman...Aetna (AET) downgraded to Buy from Conviction Buy at Goldman...Amerigroup (AGP) downgraded to Neutral from Buy at Goldman...ONEOK (OKE) downgraded to Neutral from Buy at Citigroup...Acme Packet (APKT) downgraded to Underperform from Neutral at Mizuho...RadioShack (RSH) downgraded to Equal Weight from Overweight at Morgan Stanley...Brocade (BRCD) downgraded to Market Perform from Outperform at JMP Securities...Merck (MRK) downgraded to Neutral from Buy at Davenport...CarMax (KMX) downgraded to Sector Perform from Outperform at RBC Capital...International Paper (IP) downgraded to Sector Perform from Outperform at RBC Capital...Abercrombie & Fitch (ANF) downgraded to Neutral from Outperform at Macquarie...Rowan Companies (RDC) downgraded to Neutral from Outperform at Macquarie. :theflyonthewall.com |
|
| 07:02 EDT | | VRTX |
|
| 06:06 EDT | | VRTX |
|
|
February 2, 2012
|
| 17:45 EDT |  | VRTX |
|
| 16:13 EDT |  | VRTX |
|
| 16:11 EDT | | VRTX |
|
| 16:11 EDT | | VRTX |
|
| 15:13 EDT |  | VRTX |
| theflyonthewall.com: | Vertex Pharma mentioned cautiously ahead of tonight's report at Brean Murray | | Brean Murray is cautious ahead of Vertex's report tonight and believes the company could report Incivek sales of $440M below the Street estimate of $470M, which will result in lower 2012 guidance. :theflyonthewall.com |
|
|
February 1, 2012
|
| 07:22 EDT | | VRTX |
|
|
January 31, 2012
|
| 13:35 EDT | | VRTX |
|
| 12:16 EDT |  | VRTX |
|
| 11:42 EDT | | VRTX |
|
| 11:39 EDT | | VRTX |
| theflyonthewall.com: | Vertex approval of Kalydeco earlier than expected, says Piper Jaffray | | Piper Jaffray says that while widely expected, FDA approval of Vertex's Kalydeco comes months ahead of the April 18th PDUFA date. The firm expects 2012 sales of the Cystic Fibrosis treatment to reach $117M, growing to $301M in 2013, and keeps an Overweight rating on the stock. :theflyonthewall.com |
|
| 11:28 EDT | | VRTX |
|
| 11:25 EDT | | VRTX |
|
| 11:22 EDT | | VRTX |
|
| 11:08 EDT | | VRTX |
|
| 11:07 EDT | | VRTX |
|
Subscribe for More Information